RPS6KB2 and breast carcinoma: The normal development and the lack of an apparent phenotype in S6K2−/− mice suggests that it is a potential target in the treatment of endometrial [138], gastric [139] and breast cancers [84,87,88], which have been shown to have RPS6KB2 amplification or elevated S6K2 expression.